Objectives Extracts of parts Musa spp. have been used for the treatment of various diseases in traditional medicine. Studies have shown that these extracts have hypoglycaemic properties. The aim of this work was to gather evidence on the antidiabetic effects of Musa spp. inflorescence. Methods A systematic review was conducted with searches in three electronic databases, along with manual searches. Studies evaluating the antidiabetic properties of extracts of flower or bract of the genus Musa (in vitro or in vivo) were included. Key findings Overall, 16 studies were found. The reported assays were of hypoglycaemic effects, oral glucose tolerance, inhibitory activities in carbohydrate metabolism and digestive enzymes, enhanced glucose uptake activity and popular use of the extract in patients with diabetes type 2. In vitro studies showed that use of the extract was associated with antidiabetic effects (e.g. increased glucose uptake and inhibition of carbohydrate digestion enzymes). In induced diabetic models, Musa spp. extracts showed dose-dependent glycaemic level reductions compared with pharmacological drugs (P < 0.05). Summary In general, promising results regarding antidiabetic activity were found for inflorescence of Musa spp., suggesting that this plant could represent a natural alternative therapy for treating diabetes mellitus type 2.
Introduction
Bananas and plantains (Musa spp.) belong to the Musaceae family and are one of the most important fruit crops in the world. [1] In traditional medicine, Musa spp. leaves, fruit, inflorescence, root, peels and stalks have been used for the treatment of several ailments such as diarrhoea, ulcers, pain, inflammation and diabetes mellitus. [2] With regard to diabetes mellitus, inflorescence is widely indicated [3, 4] ; for example, the consumption of cooked flowers is considered to have great potential for the control of diabetes. [5] Over the years, many studies have been conducted to investigate the biological effects of banana inflorescence. These studies have shown several biological activities, such as galactagogue, [6] anti-inflammatory, [7] antioxidant [8] and antihyperglycaemic activity. [9] Among these applications, the antidiabetic effects, including antihyperglycaemic, [10, 11] a-glucosidase and a-amylase inhibitory effects, [12, 13] stand out. Some compounds have already been identified in Musa spp., including anthocyanins, [14] phenolic acids, [14, 15] flavanones [16] and terpenoids. [16] It is known that compounds belonging to these classes have antidiabetic effects.
Anthocyanins such as delphinidin-3-rutinoside, cyanidin-3-rutinoside, petunidin-3-rutinoside, pelargonidin-3-rutinoside, peonidin-3-rutinoside and malvidin-3-rutinoside were identified in the bracts of Musa spp. [14] These compounds have been reported to be potent a-glucosidase inhibitors. [17] In addition, anthocyanins are involved in mechanisms that contribute to increased insulin sensitivity and reduced blood glucose levels, as well as the prevention of complications associated with diabetes. [18] In the flowers of Musa spp., phenolic acids such as gallic acid, catechol, protocatechuic acid, gentisic acid, vanillic acid, caffeic acid, syringic acid, p-coumaric acid, ferulic acid and epicatechin have been identified. [15, 19] These compounds have inhibitory activity on enzymes such as a-amylase and aldose reductase, contributing to the reduction in glycaemic levels and the prevention of complications. [20, 21] Among these, vanillic acid has been shown to have a protective effect against hyperinsulinaemia, hyperglycaemia and hyperlipidaemia in rats fed high-fat diets; the mechanism of action involves decreasing hepatic accumulation of nonesterified free fatty acid. [22] Flavanones such as naringenin and hesperitin are also present in the flowers of Musa spp. [16] and are known for their high antioxidant power, which has been proposed as a mechanism of action in the treatment of diabetes and its complications. [23, 24] Terpenoids, which are a-glucosidase and a-amylase inhibitors, [25] are also isolated from the flowers of Musa paradisiaca (syringin, benzyl alcohol glucoside, (6S9R)-roseoside, and 1.1 dimethylallyl alcohol b-glucoside), [26] Musa balbisiana (31-norcyclolaudenone, cycloartenol, and (24R)-4a, 24-trimethyl-5a-cholesta-8,25 (27) -dien-3b-ol) [27] and M. paradisiaca ((24R)4 a,14 a,24-trimethyl-5a-cholesta-8,25 (27) -dien-3b-ol). [28] Therefore, considering the traditional use of this plant and the presence of chemical constituents that point to the antidiabetic potential of Musa spp. inflorescence, the aim of this study was to appraise the literature through a systematic review, gathering available evidence about the use of this natural product and highlighting its antidiabetic potential.
Methods
A systematic review was conducted on the basis of recommendations from the Cochrane Collaboration and Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA). [29, 30] All steps were performed by two authors independently before reaching a consensus, and discrepancies were resolved by a third reviewer.
Search strategy and selection criteria
The search was performed in PubMed, Scopus and Web of Science electronic databases (updated in March 2017). No filters for date of publication or language were used. The search strategy was structured and built around the question 'What are the antidiabetic effects evaluated for the inflorescence extracts of Musa spp.?' The complete search strategy for PubMed is presented in the supplementary material (Appendix S1). First, titles and abstracts of identified articles were independently reviewed by two researchers, according to the inclusion criteria, in order to identify irrelevant records. The inclusion criteria were as follows: (1) belong to the genus Musa; (2) evaluate at least one in vitro or in vivo (in human or animal) antidiabetic activity; and (3) evaluate the inflorescence extract (flower or bract). In the second stage, full-text articles were independently evaluated by the same two researchers to identify any of the following exclusion criteria: studies that did not prepare extract (the use of fresh vegetable material -in natura -or dried plant); studies that evaluated an extract containing a mixture of several species; or articles reported in non-Roman characters.
Data extraction and quality assessment
Key data, such as the article's baseline characteristics (authors' names, year of publication and country), type of extract, biological activity, study methods and results, were carefully extracted from the included articles. The risk of bias in the animal studies included in this systematic review was evaluated based on the SYRCLE's RoB tool. [31] In order to establish the risk of bias, the following aspects were analysed: selection bias, performance bias, detection bias, attrition bias and reporting bias. Furthermore, in any study conducted in patients with diabetes, the risk of bias was determined using the Cochrane collaboration's tool. [29] Results and discussion
The search from electronic databases yielded a total of 2300 studies, after duplicates were removed. During assessment of titles and abstracts, 2247 articles did not meet the inclusion criteria and were excluded, leaving 53 records for fulltext screening. From these, 37 were excluded (see supplementary material - Table S1 ) and 16 articles were considered suitable for data extraction and analysis. Figure 1 illustrates the systematic study selection process.
These 16 studies [9] [10] [11] [12] [13] 15, 19, [32] [33] [34] [35] [36] [37] [38] [39] [40] were published between 1998 and 2017; 75% were from India. The majority of studies used in vivo antidiabetic models (56%). Regarding the preparation of the extract, the most applied techniques were maceration (37.5%) and Soxhlet (37.5%); ethanol was the most commonly used solvent (56.3%). Among the 16 eligible studies, it is important to highlight that only four studies evaluated the activity of a compound isolated from the inflorescence (19%) (Figure 2) .
In order to verify the biological activity of Musa spp. inflorescence, the identified studies carried out various approaches. Other characteristics of the 16 studies are presented in Table 1 and are further discussed in the results section below.
Hypoglycaemic effects and prevention of diabetic complications
Borah and Das, [33] Dhanabal et al., [34] Jawla, Kumar, and Khan, [9] Nisha and Mini, [11] Ramu et al., [38] Sundaram and Subramian, [40] and Sundaram et al. [39] performed in vivo hypoglycaemic evaluation. The assessment of this biological activity was conducted using a methanolic extract of M. paradisiaca inflorescence, [11] ethanolic extracts of flower of M. balbisiana, Musa sapientum, M. paradisiaca, and Musa sp., [9, 13, 33, 34, 39, 40] and ethanol: water (1:1) extract of flower of M. paradisiaca. [9] Figure 1 Flow chart of search and selection of published articles. Note: *The sum of excluded articles is greater than 37 because some of them met more than one exclusion criteria (see Table S1 ). [Colour figure can be viewed at wileyonlinelibrary.com] Initially, to evaluate acute oral toxicity and to establish dosage fixation, some studies [9, 33, 38] tested the administration of different concentrations of the extract. Moreover, Ramu et al. [38] also analysed isolated exposure to two constituents of Musa sp. flower: umbelliferone and lupeol, which have significant antihyperglycaemic activity in vitro. [13] Sundaram et al. [39] isolated and tested only syringin from the extract, which is considered to be an active compound with different pharmacological activities. [41] [42] [43] [44] [45] At the tested intervals, none of the concentrations showed toxicity.
For the animal model tests, Wistar rats were separated into different groups: normal control group (nondiabetic rats treated only with the vehicle), diabetic control rats (treated only with vehicle or untreated), diabetic rats (animals that received an antidiabetic drug -positive control) and diabetic animals treated with extract or with isolated compounds of M. paradisiaca (syringin, umbelliferone and lupeol). The dose of extracts administered varied between 100 and 500 mg/kg body weight, and the antidiabetic drugs used in the positive control group were insulin, [33] glibenclamide, [9, 34] gliclazide [39, 40] and metformin. [38] The diabetic state was induced via a single intraperitoneal injection of streptozotocin [11, 33, 39, 40] or alloxan monohydrate. [9, 34, 38] The animals were considered as diabetic when blood glucose values were above 200 mg/dl [11, 34, 38] or 250 mg/dl. [33, 39, 40] For the evaluation of antidiabetic effects, different biochemical markers were assessed to evaluate glycaemic levels. Significant decreases in blood glucose levels were observed with administration of the extract, [9, 11, 33, 38, 40] which were comparable to the diabetic control group. Jawla, Kumar, and Khan, [9] and Ramu et al. [38] consider this effect to be dose dependent. In addition, oral administration of syringin, [39] umbelliferone and lupeol [38] also demonstrated hypoglycaemic effects. These results are in accordance with other studies that have evaluated these isolated compounds. For example, syringin isolated from Eleutherococcus senticosus presented hypoglycaemic action in diabetic rats induced by streptozocin. [46] Further, many natural triterpenoids and coumarins appear to have promising antidiabetic properties and may be used for the prevention of diabetic complications. [25, 47] The effects of hyperglycaemia, resulting from insufficient secretion of insulin or insulin resistance, are possibly attributed to progressive b-cell failure. In untreated diabetic rats, dilatation and degranulation in islet cells has been detected, when compared to a normal control group. After treatment with the extract and its constituents, changes in the architecture of pancreatic islet cells were observed, such that they had almost returned to normal. [38] Moreover, an increase in the activities of glucokinase, pyruvate kinase and glucose-6-phosphatase-dehydrogenase was achieved with the use of the extract of M. paradisiaca tepal, [40] which indicated an effective utilization of glucose. Further, there was a reduction in the activity of two gluconeogenic enzymes, glucose-6-phosphatase and fructose-1,6-bisphosphatase, showing a regulation of gluconeogenic flux by the extract.
In addition to these trials, Dhanabal et al. [34] also evaluated the protective effect of the extract on alloxan induction of diabetes mellitus. In this model, normal rats received doses of extract (200 mg/kg) twice a day for 5 days. [34] Comparing glucose values before induction with alloxan (1st and 5th day) and after (10th day), between the treated and control groups, a protective effect promoted by the extract was observed. Glucose values were elevated in the control group, whereas in the treated group, there was maintenance of glucose levels (P < 0.02). Additionally, the extract prevented antioxidant reduction as evaluated with the following parameters -catalase, superoxide dismutase, protein, malondialdehyde and acid ascorbic estimation. Oxidative stress contributes to the progression and pathological complications of diabetes and seems to be related to the development of the disease. [48] Therefore, the extract possibly limited the damage caused by alloxan.
Prolonged high blood glucose levels lead to diverse secondary complications from diabetes. Among these complications, overproduction of sorbitol by the polyol pathway can occur; this can be avoided by inhibiting the key aldose reductase enzyme, and the formation of advanced glycation end products (AGEs), resulting from the covalent interaction between glucose and plasma proteins via a nonenzymatic process known as glycation. [49, 50] The in vitro studies of Ramu et al. [13] showed that the crude extract (95% ethanol flower extract of Musa sp. var. Nanjagud rasa bale) and its constituents (umbelliferone and lupeol) as acted as better inhibitors of aldose reductase than quercetin (positive control). Further, the inhibitory effects on glycation were evaluated using in vitro bovine serum albumin glycation and analysis of the early glycation product (fructosamine), intermediate products (protein carbonyls) and AGEs. Both compounds exhibited higher inhibitory potential across all levels, compared with the crude extract and the positive control aminoguanidine. [13] Another complication caused by chronic hyperglycaemia is the acceleration of protein catabolism and excess lipolysis, leading to total protein reduction, increased lipid profile and weight loss. [51] [52] [53] Treatment with the extract and the isolated compounds enhanced total protein [39] and haemoglobin levels. [38, 39] Furthermore, at the end of the studies of Borah and Das [33] and Ramu et al., [38] the treated diabetic groups exhibited a significant reduction in total blood cholesterol, serum triglycerides and serum lowdensity-lipoprotein, while there were significant increases in serum high-density-lipoprotein and body weight. Borah and Das [33] attributed this antilipidaemic activity to the presence of pectins (which elevate the viscosity of the gastrointestinal contents, and hence, reduce the absorption and digestion of carbohydrates), saponins (which reduce the cholesterol absorption in the intestinal lumen and stimulate excretion of bile acids), tannins (which decrease dietary absorption of cholesterol) and gallic acid (which inhibits cholesterol esterase and enhances faecal excretion of bile acids). These results are in accordance with other previous reports.
[ [54] [55] [56] [57] [58] In addition to excessive protein degradation in the diabetic rats, there was an augmentation of irreversible glycation of several proteins, including haemoglobin. This produces glycosylated haemoglobin (HbA1c), considered an important biomarker for diabetes. [54] [55] [56] [57] [58] The majority of the included studies assessed this parameter and identified a significant reduction in HbA1c (P < 0.05) in the group treated with the extract and active compounds isolated from the extract of banana flower/inflorescence, when compared to the control group. [11, [38] [39] [40] Diabetes is also characterized by renal impairment, culminating in glycosuria (excretion of glucose in the urine), as well as elevated blood urea and serum creatinine levels. [59, 60] These abnormalities reverted to near normal levels, that is, decreased renal glucose excretion, blood urea, serum uric acid and serum creatinine levels after the use of the extract and its constituents. [38, 39] Apart from renal impairment, the liver is also compromised by hyperglycaemia, due to it being associated with glucose storage and metabolism. [61] The histopathological analysis conducted by Nisha and Mini [11] in diabetic animals demonstrated hepatocellular damage in the form of severe macrovesicular steatosis, microcellular fatty changes and extensive vacuolization, with disappearance of nuclei and periportal inflammation. However, these alterations were optimized back to near normal after treatment with the extract. The hepatotoxic effect was also confirmed by the elevation of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) enzymes in the diabetic groups, while there was a reduction in the levels of these enzymes in the groups treated with the extract [11, 38] or its constituents. [39] Glycogen is a polysaccharide that is the principal storage form of glucose, and its production is regulated through insulin's action. In the diabetic state, glycogen concentrations are reduced; however, after the administration of the extract and isolated compounds (umbelliferone and lupeol), these polysaccharide levels were enhanced. [11, 38] Common symptoms described in diabetes mellitus are polydipsia, polyphagia and polyuria, which are related to osmotic alterations because of impaired glucose uptake. [62] . Ramu et al. [38] reported these symptoms in all diabetic groups of rats. At the end of the experiment, these diabetic signs were reversed due to the administration of the extract and the isolated compounds.
Another parameter to assess the antidiabetic action is delayed intestinal glucose absorption, which culminates in a decrease in blood glucose levels, proposed in the work of Borah and Das. [33] This mechanism was evaluated for a flower and inflorescence stalk extract, culminating in a significant reduction in both treatment groups, but with a greater result with the flower extract. According to Borah and Das, [33] this action of these extracts can be attributed to the pectins found in the flower ethanolic extract, and the saponins and tannins present in both extracts. These results are in agreement with other reports described in the literature. [54] [55] [56] [57] In summary, oral administration of the extract and its constituents demonstrated hypoglycaemic properties. Among the included studies, hypoglycaemic activity is attributed to different compounds, mainly related to the presence of glycosides such as saponins, [9, 33, 34, 40] polyphenols such as gallic acid, epicathechin, and tannins, [9, 33, 34, 40] flavonoids, e.g., quercetin, [9, 11, 34, 40] polysaccharides, e.g., pectin, [9, 11, 40] sterols, [34, 40] triterpenes, and alkaloids. [40] Furthermore, Ramu et al. [38] evaluated compounds isolated from an extract of the banana flower. Umbelliferone and lupeol were considered to be antidiabetic compounds, justified by the regeneration of b-cells, and hence, leading to an improvement in insulin secretion with subsequent glycaemic reduction. [13, [63] [64] [65] [66] [67] Syringin demonstrated effects on glucose homeostasis that may be due to its effects on glucose uptake and glycogen synthesis. [46] Oral glucose tolerance Jawla, Kumar, and Khan [9] conducted an in vivo hypoglycaemic evaluation in rats with induced diabetes, and evaluated the effect of flower extract on glucose-loaded normal rats. The assessment of this oral tolerance test was conducted after overnight fasting (16 h) using distilled water (vehicle), ethanol and ethanol:water (1:1) extracts of flowers at three doses (100, 250 and 500 mg/kg). Glibenclamide was used as the standard oral hypoglycaemic drug (0.2 mg/kg). In order to compare the results, rats were separated into different groups: one control group (rats treated only with vehicle), one positive group (rats that received glibenclamide) and groups of animals treated with different doses of different extracts of M. paradisiaca. Glucose (4 g/kg) was fed to rats 60 min after treatment, and for the evaluation of the effects, blood glucose levels were measured after 0, 30, 60, 90, 120, 240 and 360 min. A significant decrease in blood glucose levels was observed with all three doses of the extract administered, after 30 min, in glucose-loaded rats; this was comparable to glibenclamide. No difference was observed between the lowest and highest dose administered. In addition, the different extracts (ethanol and ethanol:water (1:1)) were similar in their reduction of blood glucose over time. Phytochemical screening of M. paradisiaca flowers revealed the presence of glycosides, flavonoids, saponins, and tannins in the ethanol and ethanol:water (1:1) extracts. The authors suggested that the potent antihyperglycaemic properties observed may be attributed to these components. Flavonoids are known for their high antioxidant power, which has been proposed as a mechanism of action in the treatment of diabetes and its complications. [23, 24] However, further investigation is required to better characterize the active principles. [9] Aguilara et al. [12] also evaluated the effect of M. paradisiaca flower extracts on glucose tolerance; however, the test was performed in temporarily hyperglycaemic healthy rabbits. [12] The assessment of this oral tolerance test was performed with New Zealand adult male rabbits weighing between 2.5 and 3.5 kg after overnight fasting (18 h). The plant extract was obtained by decoction of 40 g of the dried plant slowly boiled in 300 ml of water for 10 min. Then, the liquid decoction was filtered and directly administered to the animals (4 ml/kg using a gastric tube). Distilled water was used as control, and tolbutamide was used as the standard oral hypoglycaemic drug (40 mg/kg). Rabbits were separated into different groups: two control groups (rabbits treated only with vehicle), two positive groups (rabbits that received tolbutamide) and one group of animals treated with M. paradisiaca extract. A 50% glucose solution was applied subcutaneously (3 g glucose/kg), two times, at time 0 and 60 min. The blood glucose levels were measured at intervals of 60 min for 5 h after injection of the first glucose load. The percentage of the decrease in glycemia, caused by the hyperglycaemic peak and area under the curve were estimated. A reduction in glucose levels was observed 60 min after glucose load. A decrease of 17.0% in the hyperglycaemic peak was observed in rabbits treated with the plant extract, whereas for tolbutamide, the observed decrease was 15.7%. Regarding the area under the curve, the authors reported that the plant extract also caused a significant reduction (18.0%) in their control group. Tolbutamide caused a reduction in the area under the curve of 16.6%. In this study, the authors evaluated the extract produced according to its traditional use in Mexico, and no phytochemical screening was performed. The authors suggest that this plant must be considered as an excellent candidate for future studies to elucidate the mechanisms of its hypoglycaemic activity, as well as for the isolation and identification of its active hypoglycaemic substances. [12] Despite the differences between these studies in the procedures by which the extracts were obtained, the study protocols, and the animal models used (rats or rabbits), [9, 12] there are some similarities in the solvent extractor and doses evaluated. Jawla, Kumar, and Khan [9] evaluated the range of 100 to 500 mg/kg and Aguilara et al. [12] used a dose of 4 ml/kg, equivalent to 259 mg/kg of extract. Another difference is that one study used rats [9] as experimental animals while the other rabbits. [12] Both authors reported on the hypoglycaemic potential of M. paradisiaca in the first hour after administration of the extract, and results of the hypoglycaemic properties are convergent.
Improvement in glucose uptake
Two included articles evaluated the effect of Musa sp. cv. Elakki bale and M. paradisiaca flowers on the improvement in glucose uptake. [32, 68] Both evaluated the uptake of glucose using its fluorescent analogue 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose (2-NBDG). They analysed phenolic acids via high-performance liquid chromatography (HPLC) to determine the cytotoxic effect of the extracts. However, they diverged in the cellular model, type of positive control and extract composition. Further, unlike Arun et al., [32] the study of Bhaskar, Salimath, and Nandini [68] quantitated total phenolic compounds using a Folin-Ciocalteu reagent.
Ehrlich ascites tumour (EAT) cells were chosen as a cellular model by Bhaskar and colleagues. [68] This model was also utilized in other studies of glucose transport. [69] [70] [71] This model uses insulin (between 0.4-6 IU) as a positive control in the glucose uptake test. The flower and pseudostem of the Musa sp. were selected for extraction of phytochemicals with different solvents.
The incubation period of the cells with different doses of acetone, methanol, ethanol and aqueous extracts (between 2-1000 lg/ml) was 5 min at 37°C. Then, 2-NBDG (1 mM) was added with buffer and incubated together for 30 min at 37°C. In the sequence, the cells were centrifuged, washed with buffer, lysed, suspended in buffer with Triton X-100 and sonicated. Finally, they were centrifuged again and the supernatant was analysed by spectrofluorimeter to measure the fluorescent analogue of glucose. [68] The results were given as net glucose uptake. They were obtained by subtracting the values of the control from that of the cells pretreated with the extract and 2-NBDG. The basal glucose uptake (EAT cells + 2-NBDG) was considered as a control. [68] At lower concentrations of extracts, a dose-dependent increase in glucose uptake was observed for flower and pseudostem extracts. However, the improvement in uptake was not dose proportional with concentrations above 50 lg/ml. Furthermore, uptake inhibition was noted at higher doses of pseudostem extracts, which was not due to cytotoxic effects. Experiments after staining of cells with Trypan blue confirmed the viability of cellular function. [68] The decreasing order of efficiency of the extracts, in terms of glucose uptake, was aqueous, methanol, ethanol and acetone extracts. Through the HPLC analysis, the following major phenolic acids were identified: gallic acid, protocatechuic acid, gentisic acid, catechol and epicatechin. Other unidentified substances were also observed. Further, the methanol extract showed a higher amount of total phenolic acids compared to aqueous extract. Thus, these results suggest that other substances, in addition to phenolic phytochemicals, could have influenced glucose uptake in the EAT cells. [68] In the research by Arun et al., [32] the cellular model was L6 myoblasts. These L6 skeletal muscle cells have been extensively used in recent investigations of phytochemical compounds with antidiabetic effects. [72, 73] This study used rosiglitazone (100 nM) as a positive control and the entire inflorescence for the extractions. The L6 cells differentiated were pretreated with 50 and 100 lg/ ml methanol extract for 24 h, and were then washed with buffer and incubated with 2-NBDG (0.1 mM) for 30 min. After that, the cells were washed with buffer, trypsinized and resuspended in buffer. The quantitation of the fluorescent analogue of glucose was completed by fluorescence activated cell sorting (BD FACS Aria II, BD Bioscience, USA) and BD FACS Diva software. The cytotoxic effects of the extracts were assessed using a 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. [32] The results showed a dose dependent increase in glucose uptake of L6 myoblast cells pretreated with methanol extract. The HPLC analyses highlighted the presence of gallic acid, catechol, chlorogenic acid, caffeic acid, syringic acid, p-coumaric acid, ferulic acid, ellagic acid, myricetin, cinnamic acid, kaempferol and apigenin in this extract. [32] Thus, considering the results of both studies, it is possible to associate the in vitro improvement in glucose uptake activity in a cellular model to the phenolic compounds of Musa sp. The aqueous and methanol extracts of inflorescence of this genus have promising antidiabetic potential. However, divergence between the results of Arun et al. [32] and Bhaskar, Salimath, and Nandini [68] was observed when higher doses of the extracts were considered. A possible cause for this is the evaluation of glucose uptake on different glucose transporters. EAT cells have GLUT1 and GLUT3 while L6 myoblast cells have GLUT1 and GLUT4. [69, 74] In the literature, other cellular types have been used to analyse glucose uptake, such as 3T3-L1 cells and sheep erythrocytes. [75] [76] [77] Another possibility could be differences in the extract composition, since Bhaskar, Salimath, and Nandini [68] selected parts of the inflorescence while Arun et al. [32] used the entire inflorescence. In addition, the authors used very distinct contact times between the extracts and the cells.
Inhibition of carbohydrate digestion enzymes
Inhibition of carbohydrate digestion is a basic pathway used in antidiabetic drugs such acarbose and miglitol. [78] Six studies [10, 13, 19, 32, 36, 37] included in our systematic review reported data on the determination of the a-glucosidase inhibitory activity of Musa spp. These researchers used a spectrophotometric method with p-nitrophenyl-a-D-glucopyranoside (pNPG) as a substrate and a-glucosidase from baker's yeast. [10, 13, 19, 32, 37] The inhibition of a-amylase activity was also determined by a spectrophotometric method, using starch solution as a substrate, porcine a-amylase, and DNS reagent, [13, 37] iodine, [32] or no reagent. [36] Acarbose was chosen as positive control in all the six studies.
Ramu et al. [13] evaluated a 95% ethanol flower extract of Musa sp. var. Nanjagud rasa bale. Further, two compounds were isolated from this extract by silica gel column chromatographic separation (umbelliferone and lupeol) and tested. [13] Both compounds and their families have been reported to be compounds with a-amylase and a-glucosidase inhibition properties, [21, 79, 80] which was confirmed by this study. The crude extract and its compounds exhibited strong inhibition of a-glucosidase (IC 50 7.79 lg/ml -crude extract; 9.68 lg/ml -acarbose) and a-amylase (IC 50 36.05 lg/ml -crude extract; 29.71 lg/ml -acarbose). Comparing the isolated compounds, umbelliferone was a more potent inhibitor than lupeol. A kinetic study of a-glucosidase inhibition was conducted to clarify the mechanism of binding of the compounds. The enzyme was incubated with different concentrations of pNPG (0.25-4 mM) with and without umbelliferone and lupeol at IC 20 , IC 40 , and IC 50 concentrations. From the interpretation of Lineweaver-Burk plots, both compounds appeared to inhibit the enzyme via a noncompetitive mechanism. [13] Another study [19] also investigated the inhibitory activity of a 95% ethanol extract of Musa spp. var. Baxijiao flowers. These authors evaluated petroleum ether, ethyl acetate, nbutanol and aqueous fractions, with the objective of identifying compounds related to this activity. The crude extract presented with the highest inhibitory activity, followed by the fractions of ethyl acetate and petroleum ether. These fractions were then subjected to fractionation, purification and isolation of compounds. The identified compounds were as follows: vanillic acid, ferulic acid, and b-sitosterol in the petroleum ether fraction, and daucosterol and 9-(4 0 -hydroxyphenyl)-2-methoxyphenalen-1-one in the ethyl acetate fraction. Among these isolated compounds, the latter three showed superior activity compared to acarbose. The mechanism of binding of these compounds was studied by Lineweaver-Burk plot analysis, indicating a competitive mode for the sterols and a mixed-type inhibition for phenylphenalenone. [19] Comparing the IC 50 values obtained by these two abovementioned studies, we verified that the extract evaluated by Sheng et al. [19] presented with a-glucosidase inhibitory activity three times greater than acarbose, while the other extract presented as 1.2 times greater than the same control. This result can be attributed to a difference in the profile of chemical constituents between the assessed plants. This is supported by the different activities of the isolated compounds in the study by Ramu et al., [13] which showed activity very close to the crude extract, and the study by Sheng et al., [19] which presented with much higher activity than the control, about 200 times. This kind of comparison between different species and cultivars of Musa sp. was performed by Marikkar et al. [37] Hydroalcoholic extracts (80%), at 200 lg/ml, of six different cultivars of banana flowers (Musa acuminata cv. P. berangan, cv. P. susu, and cv. P. ma; M. balbisiana cv. P. abu and P. nipah; M. paradisiaca cv. P. rastali) showed inhibitory activity on carbohydrate-hydrolysing enzymes. [37] Susu also showed a high phenolic and flavonoid content and antioxidant capacity among the six cultivars, which could contribute to its strong antihyperglycaemic activity. This is in accordance with studies on the potent a-glucosidase inhibitory activity of some flavonoids and phenolics. [21, 67] In the study conducted by Dineshkumar, Mitra, and Manjunatha, [36] which evaluated the extract of flowers of M. paradisiaca prepared by successive maceration with petroleum ether, hexane, chloroform, ethanol and water, only the extract in chloroform presented with a-amylase inhibitory activity (IC 50 97.80 AE 0.73 lg/ml). [36] On the other hand, a study comparing the a-glucosidase inhibitory activities of tepal extracts of ethanol, methanol, and water of M. paradisiaca, showed that methanol was the most potent inhibitor (IC 50 200, 60, and 360 lg/ml, respectively). [10] However, under this assay, acarbose (positive control) was not potent enough to inhibit a-glucosidase. The methanol extract exhibited higher inhibitory activity of carbohydrate digestive enzymes when compared to the ethyl acetate extract (methanol extract: IC 50 166.14 and 106.37 lg/ml, and ethyl acetate extract: IC 50 183.96 and 140.03 lg/ml, for a-amylase and aglucosidase, respectively). [32] In addition, methanol extract showed antiglycation properties, as in the study by Ramu et al. [13] This activity was related to the presence of the polyphenol compounds in the extract, such as kaempferol.
Antidiabetic effects in humans
Among the selected articles, only one evaluated the antidiabetic activity of Musa spp. flowers in humans. [35] This study evaluated the antidiabetic potential of an aqueous extract of M. sapientum in volunteers diagnosed with type 2 diabetes (n = 40; random selection). The extract was prepared in water by overnight maceration using 500 g of dried plant and one litre of purified water, and unlike the animal studies, the administered extract was not dried and resuspended in a vehicle for administration. The volunteers were divided into an experimental group (20 volunteers received the extracts, 5 ml/day, over 2 months) and a control group (20 volunteers received water only). Anthropometrical, clinical and blood biochemistry parameters (fasting blood glucose, triglycerides, total cholesterol, high-density-lipoprotein, low-densitylipoprotein, and very low-density-lipoprotein; 12 h fasting) were evaluated prior to the study and at the end of the study. The results were statistically analysed, but the method for doing so was not specified (statistical significance = P < 0.05). According the authors, no significant differences in biochemical parameters were observed between the experimental and the control group. [35] However, when compared to studies with animal models, the administered dose was much lower: 100 to 500 mg of dry extract per kilo for animals versus only 5 ml of the prepared extract per day for volunteers (mean weight of 76 kg). Thus, further clinical studies with higher doses should be conducted in order to strengthen this evidence.
Assessment of studies
The sequence generation and allocation concealment were not detailed in any included experimental studies, contributing to the occurrence of high risk of bias. Furthermore, none of the studies executed adequate blinding between the animal caregivers and investigators.
The assessment of similarity in baseline characteristics between the experimental and control groups was considered in the distribution of groups in the included studies, leading to a low risk of bias for this domain. Housing conditions of animals in different treatment groups were similar in seven studies (87.5%), with only two studies (25%) not reporting these conditions. The results of assessment of the methodological quality of the animal intervention studies included in this systematic review are presented in Figures 3 and 4 .
Regarding the human study by Dineshkumar, Mitra, and Manjunatha, [35] random sequence generation, incomplete outcome data, selective reporting and other biases were considered to be of low risk of bias. [35] The authors were not clear when reporting allocation concealment and the items 'blinding of participants and personnel' and 'blinding of outcome assessment' were classified as high risk of bias ( Figures 5 and 6 ).
Conclusions
The identification of novel compounds and the evaluation of potentially useful natural therapies are paramount for clinical practice. Our systematic review evaluated the proprieties of Musa spp. as a natural alternative for management of diabetes mellitus. In total, 16 articles evaluating the antidiabetic activity of Musa spp. and its cultivars were included. Only one study evaluated the antidiabetic effect in humans, but there were no significant differences observed between the treated and the control groups. However, the administered dose was low (5 ml of fresh extract). In the animal-induced diabetic models, the plant extracts showed an equivalent glycaemic level reduction, considered to be dose dependent, when compared to various pharmacological drugs (e.g. insulin, glibenclamide, gliclazide and metformin). Additionally, the administration of this plant extract was able to reverse abnormalities in the pancreatic islet caused by elevated levels of insulin. These effects are probably due to the regulation of enzymes in carbohydrate metabolism and gluconeogenic flux caused by the extract components. Moreover, antioxidant properties of the extracts were related to a protective effect against the damage caused by toxic inducers of diabetes. In vitro studies associated the antidiabetic effects of the extracts to an increase in glucose uptake and inhibition of carbohydrate digestion enzymes.
In general, promising results regarding antidiabetic activity were found with inflorescence of Musa spp. However, more studies with higher methodological quality and low risk of bias for some domains (e.g. sequence generation and allocation concealment, blinding, blinding of participants and personnel, and blinding of outcome assessment) are necessary to clarify the phytochemical diversity of this plant and its mechanism of action. Musa spp. might represent a natural alternative therapy for diabetes mellitus in the future, and its isolated phytochemicals may contribute to the development of new drugs.
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